Getting to treatment earlier.


CTD refers to a variety of autoimmune disorders with signs and symptoms that overlap with various other diseases, making diagnosis very difficult. That’s why we offer a comprehensive line of test options including NOVA Lite®, QUANTA Lite®, and QUANTA Flash® assays. We continue to develop new assays to help diagnose and stratify CTD disorders, like ­HMGCR for necrotizing myopathy.

HIGHLIGHTS
  • Giving patients earlier answers.
    Patients gain confidence when their diagnosis is supported by clinical labs results. New biomarkers like HMGCR offer help confirm a diagnosis in areas such as necrotizing myopathy where existing tests don’t cover all forms of the disease.
  • Improving workflow in the lab.
    Assays like QUANTA Flash dsDNA, utilize random access testing to eliminate batching and improve efficiency in your lab.
  • Enhancing clinical diagnosis and assessment.
    Clinicians appreciate the excellent performance characteristics of our CTD assays to aid in the assessment of complex symptoms and diseases.

Reagents


Description
Package size
Part number
Documents
Description
Package size
Part number
Documents